SCHEMBL2498615

SCHEMBL2498615

COC(=O)c1ccc(-c2cc(OC)ccc2F)c(C2CCCCCC2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.44
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
FFAR1 O14842 5/20 0.41
MAPT P10636 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
BRD4 O60885 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
ROCK2 O75116 1/20 0.40
HPGD P15428 1/20 0.39
IDH2 P48735 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2312137 0.85 FFAR1 (0.56) FFAR1
SCHEMBL2498679 0.85 FFAR1 (0.56) FFAR1
SCHEMBL2498140 0.85 FFAR1 (0.56) FFAR1
SCHEMBL3873850 0.85 CA1 (0.44) ALDH1A1SMN1; SMN2ATMNPSR1ALOX5AP
SCHEMBL2500009 0.84 IDH1 (0.41) ALDH1A1SMN1; SMN2CA1CA2FFAR1
SCHEMBL3713880 0.84 IDH2 (0.40) ALDH1A1SMN1; SMN2ATMNPSR1ALOX5AP
SCHEMBL2500183 0.84 IDH2 (0.40) ALDH1A1SMN1; SMN2ATMNPSR1ALOX5AP
SCHEMBL2504360 0.83 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2ATMNPSR1PTGDR2
SCHEMBL2315121 0.81 FFAR1 (0.41) FFAR1ROCK2
SCHEMBL2498215 0.81 LMNA (0.40) ALDH1A1SMN1; SMN2ATMNPSR1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
EP-2205548-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS Amgen, Inc (US) 2010-07-14 EP disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 ALDH1A1 1149/4885SMN1; SMN2 4745/4885ATM 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.